What to Look for in PTSD Treatment in Fort Lauderdale

Choosing a program while you’re in crisis is a brutal ask. You’re reading glossy sites with palm trees and sunrise logos, and somewhere underneath that is a real question: can this place keep you safe tonight, and get you to the therapy that actually treats PTSD?

The honest shortcut is to stop grading programs on amenities and start grading them on sequence. A credible dual-diagnosis provider in Fort Lauderdale moves you through a predictable clinical order:

1. a real intake assessment that screens trauma symptoms, substance use, withdrawal risk, and suicide risk;
2. medical stabilization when your body needs it;
3. concurrent treatment for PTSD and the substance use disorder rather than one before the other;
4. a medication plan that follows current guidance; and
5. a transition that hands you off to someone who already knows your chart.

The rest of this piece gives you the specific questions to ask at each stage, so you can pressure-test any local program against the same standard a referring clinician would use. You don’t need to become an expert. You just need to recognize what a serious answer sounds like.

If a program is ready to pitch you a treatment plan in the first ten minutes of a phone call, something is wrong. A clinically serious intake is slower, more boring, and far more specific. It asks about things that feel invasive because the answers change what safe care looks like for you.

At minimum, a real dual-diagnosis intake covers five areas:

1. Trauma symptom screening: not just “do you have PTSD,” but structured questions about intrusions, avoidance, hyperarousal, dissociation, and how long symptoms have been present. The VA/DoD guideline frames this as the foundation of any PTSD plan, because the diagnosis determines which therapies are indicated and which are not ¹.
2. A substance use and withdrawal risk assessment. The intake clinician should ask what you use, how much, how often, when you last used, and whether you have ever had seizures, DTs, or complicated withdrawal before. For alcohol and benzodiazepines, those answers decide whether you need medical monitoring tonight or can start outpatient care in a week ¹.
3. Direct suicide risk questioning. Not a form you check. A person asking you, out loud, about current thoughts of suicide, any preparatory behavior, access to means, and past attempts. The National Center for PTSD is explicit that this belongs in a complete PTSD evaluation, especially when trauma symptoms sit alongside intoxication, withdrawal, or depression ⁸.
4. Medical comorbidities: pregnancy, cardiac history, seizure history, liver function, chronic pain, head injuries. These determine what medications are safe and whether you need a higher level of monitoring during stabilization.
5. Medication reconciliation. Every prescription, every over-the-counter, every supplement, every substance, with doses and last-taken times. This is where polysubstance risk gets caught before someone writes an order that interacts badly.

If a provider skips any of these, or hands you a plan before completing them, that is your signal to keep looking. A good intake can feel exhausting. That is the point — it is doing the work of protecting you before anyone promises anything.

Not everyone with PTSD and a substance use disorder needs an inpatient bed tonight. But some people absolutely do, and the difference is not about willpower or how badly you want to get better. It’s about what your body is doing while your nervous system is already in overdrive.

Alcohol and benzodiazepines are the two substances where unsupervised withdrawal can kill you. If you have been drinking heavily every day, or taking Xanax, Klonopin, Ativan, or Valium at doses above what was prescribed, or combining the two, you belong in a setting where someone is checking your blood pressure, pulse, and withdrawal symptoms on a schedule — not at home with a family member Googling symptoms at 3 a.m. A credible program will ask about seizure history, prior DTs, how many drinks per day, and when you last used, and will route you to medically supervised withdrawal if those answers warrant it ¹.

Opioids are different. Opioid withdrawal is miserable but rarely lethal on its own. The danger is what comes after: tolerance drops fast, and a return to a previous dose can be fatal. For opioid-involved patients, acute stabilization should include an honest conversation about buprenorphine or methadone induction, naloxone in hand at discharge, and a prescriber who will keep that medication going after you leave. SAMHSA is explicit that combining methadone or other opioids with alcohol or benzodiazepines carries respiratory-depression and overdose risk, which is exactly why the intake clinician needs the full substance list before anyone writes an order ^{10, 11}.

Stimulants — cocaine, meth, prescription amphetamines — generally do not require medical detox for the body, but the psychiatric picture during the crash can be severe: suicidal thinking, paranoia, psychotic symptoms, and dangerous sleep deprivation. For a PTSD patient, that overlap matters. A program should treat stimulant stabilization as a psychiatric monitoring question, not an afterthought.

What you want to hear from a provider is specificity. Not “we handle everything,” but a clear statement of which substances they medically manage on-site, which they coordinate elsewhere, how often vitals and withdrawal scales are checked, and who is awake and clinically licensed at 2 a.m. If you cannot get those answers from the admissions call, you have your answer about the program.

For years, the standard move was to tell people with PTSD and a substance use disorder: get clean, prove you can stay clean for 30 or 60 or 90 days, and then we’ll start trauma work. The logic sounded reasonable. The data has not been kind to it.

The current VA/DoD guideline and the National Center for PTSD are explicit: having a substance use disorder should not be a barrier to receiving evidence-based PTSD treatment, and patients do not need to be abstinent to start or benefit from it ^{1, 2}. The 2024 state-of-the-science review on comorbid PTSD and substance use disorder reaches the same conclusion, and the 2023 ESTSS expert consensus goes a step further, naming trauma-focused psychological intervention combined with substance use treatment as the most effective approach for PTSD symptoms in this population ^{7, 4}.

The strongest single piece of evidence is Project Harmony, an individual-patient-data meta-analysis of behavioral and pharmacologic trials for comorbid PTSD and alcohol or other drug use disorders. At end of treatment, combining trauma-focused therapy with pharmacotherapy for substance use produced a Cohen’s d of -0.92 for PTSD severity and -1.10 for alcohol-use severity, compared with treatment as usual ⁵. Effect sizes above 0.8 are considered large in clinical research. These are not. These are substantial reductions in two conditions at the same time, in patients who, under the older sequential model, would have been told to come back later.

What this means for you, standing in front of a Fort Lauderdale program’s website: a provider who tells you that you must complete 90 days of sobriety before any trauma work can begin is practicing against the current evidence base. A provider who says they will start screening for PTSD during stabilization, offer or refer you to prolonged exposure, cognitive processing therapy, or EMDR as soon as it is clinically appropriate, and keep your substance use treatment running in parallel is practicing with it.

The caveat worth saying out loud: “concurrent” does not mean “on day one of acute withdrawal.” Trauma-focused therapy requires a nervous system that can tolerate the work. The question is not whether to wait, but who decides when to begin — a clinician assessing your readiness week by week, or a policy that sets an arbitrary clock. The evidence favors the clinician.

When you ask a Fort Lauderdale program what kind of therapy they do, vague answers are a tell. “Trauma-informed care” is not a therapy. “Holistic healing” is not a therapy. You want names, protocols, and the clinicians trained to deliver them.

Four therapies carry the strongest evidence for PTSD, and they are the ones a credible program should be able to list without hesitation:

• Prolonged exposure (PE) walks you through the trauma memory and the real-world situations you have been avoiding, in a structured way, over roughly 8 to 15 sessions.
• Cognitive processing therapy (CPT) focuses on the beliefs the trauma left behind — about yourself, other people, safety, trust — and gives you tools to work with them on paper and out loud.
• Trauma-focused cognitive behavioral therapy (TF-CBT) combines exposure elements with cognitive and skills work.
• EMDR uses bilateral stimulation while you recall trauma material, following its own eight-phase protocol.

All four are manualized, individual, and trauma-focused — the exact qualities the state-of-the-science review and the ESTSS expert consensus name as the most efficacious psychotherapies for PTSD with co-occurring substance use disorder ^{3, 4, 7}.

A few practical questions tell you whether a program actually delivers these or just references them:

• Which of the four do your clinicians have formal training in, and how recently?
• Do you follow the published protocols, or a modified version?
• How many sessions does a typical course run?
• Will the same therapist see me each week, or does the schedule rotate?
• Can trauma work continue while I am still using, or still on medication for my substance use disorder — and if not, what is your reasoning?

That last question matters most. A program whose answer is “we need you abstinent first” is operating on a model the current guidelines have moved away from ^{1, 2}. A program that says, “a clinician will assess your readiness session by session, and we will coordinate with your prescriber,” is operating on the one they have moved toward.

Medication for PTSD is a smaller part of the picture than most people assume, and that is actually the honest answer. Trauma-focused psychotherapy carries the strongest evidence. Medication supports the work, treats co-occurring depression or anxiety, and helps manage substance use disorder — but it does not replace therapy for PTSD, and no medication has been established specifically for the PTSD plus substance use combination ⁷.

For PTSD symptoms themselves, the first-line pharmacologic options a Fort Lauderdale prescriber should be able to discuss are the SSRIs sertraline and paroxetine, and the SNRI venlafaxine. These are the medications the VA/DoD guideline recommends for patients who prefer medication, cannot access trauma-focused therapy immediately, or want both at once ¹. Prazosin may come up for trauma-related nightmares and sleep disruption, as an add-on rather than a stand-alone PTSD treatment.

Then there are the medications that should raise your eyebrow when a program leads with them.

If opioids are part of your history, the medication conversation extends to buprenorphine, methadone, or naltrexone for opioid use disorder, and to naloxone in your hand at discharge. SAMHSA is explicit that combining methadone or other opioids with alcohol or benzodiazepines carries respiratory-depression and overdose risk, so the prescriber writing your PTSD medications needs to be looking at the same chart as the prescriber managing your opioid use disorder — ideally the same person, or two people who talk ^{10, 11}. For alcohol use disorder, naltrexone and acamprosate are the FDA-approved options worth asking about alongside your PTSD plan.

The question to ask any prescriber: who else sees this list, and when do you call them? A good answer names a specific outpatient psychiatrist, primary care doctor, or opioid treatment program and describes the handoff. A vague answer about “coordinating as needed” is not a plan.

This is the part that often gets handled on a clipboard, and it shouldn’t be. For a patient with PTSD and a substance use disorder, suicide risk and overdose risk are not two separate checkboxes — they overlap in ways that need a person asking real questions, not a form you sign at admission.

On the suicide side, what you want to hear is specificity. A clinician asking you directly about current thoughts of suicide, any plan or preparatory behavior, access to firearms or stockpiled medications, and past attempts — then repeating that assessment, not just doing it once at intake. The National Center for PTSD is clear that direct questions belong in a complete PTSD evaluation, especially when trauma symptoms sit alongside intoxication, withdrawal, or depression, and that risk is dynamic rather than something you measure once and file away ⁸. A good program also produces a written safety plan with you: warning signs you recognize, people you can call, means restriction steps, and the number for the clinician on call after hours.

On the overdose side, the question is whether the program treats naloxone as standard equipment. For anyone with opioid exposure — current, recent, or historical — naloxone in your hand at discharge, with your family members trained to use it, is not optional. SAMHSA guidance treats overdose education and naloxone distribution as part of basic opioid treatment, alongside honest conversations about reduced tolerance after a period of abstinence and the extra respiratory-depression risk when opioids combine with alcohol or benzodiazepines ^{10, 11}. If a Fort Lauderdale program cannot tell you how they handle naloxone, safety planning, and overnight escalation, those are the answers you needed.

Here is the part of program evaluation that most readers underweight because it feels administrative: what happens the day you leave. The strongest intake, the safest stabilization, and the most evidence-based therapy can all be undone by a discharge that drops you back into your life with a phone number on a piece of paper and no appointment on anyone’s calendar.

CDC data from 2024 is blunt about the stakes. Among people who died from overdose that year, 37% had evidence of a mental-health diagnosis, and about 32% had ever been treated for a mental-health or substance-use disorder ¹³. Prior contact with care is not the same as current contact with care. The gap between the two is where people are lost, and it is the gap discharge planning exists to close.

A credible transition is specific and warm, not generic and cold. Warm means the clinician who treated you calls or video-conferences the outpatient prescriber, the trauma therapist, and the opioid treatment program before you walk out — not after. Specific means you leave with a named provider, a scheduled first appointment inside the window that current care should begin, and a copy of your medication list, safety plan, and current PTSD and substance-use disorder assessments going to each person on your team. For opioid-involved patients, specific also means naloxone in your hand and a plan for the first week of medication for opioid use disorder, because tolerance drops quickly during any gap in use ^{10, 11}.

Ask a Fort Lauderdale program three questions about discharge, early in your call, not at the end:

1. Who schedules my first outpatient appointment, and before I leave or after?
2. What does your team send to that provider, and when?
3. Who do I call at 10 p.m. on day three if I am not okay?

If the answers are vague, you are hearing how your handoff will go. If the answers name people, timelines, and documents, you are hearing a program that treats the days after stabilization as part of the treatment itself.

Broward County is wide, and “Fort Lauderdale” on a website can mean a facility near Victoria Park, something off Federal Highway near Progresso Village, or an address closer to Rio Vista, Colee Hammock, or South Middle River ¹². That matters for one practical reason: if your continuing-care therapist, your prescriber, and your opioid treatment program all sit on opposite sides of I-95, your odds of making every appointment in the first month drop. Ask where the program is, where the aftercare appointments will be, and how you are expected to get between them.

On insurance, get three things in writing before you admit, not after:

1. In-network status for the specific facility and the specific level of care being proposed — detox, residential, PHP, IOP are billed differently.
2. Your out-of-pocket exposure: deductible remaining, coinsurance, and any per-day facility fee.
3. Whether the therapist and prescriber who will see you after discharge are also in-network, because an in-network detox feeding you into an out-of-network outpatient plan can leave you with a bill that undermines the whole plan.

Also verify, in writing: who releases your records to your outpatient team, and when. A signed release at admission is how your trauma assessment, medication list, and safety plan actually arrive on the next clinician’s desk.

Keep this list next to the phone. You do not need to ask every question in order — but if a program cannot answer most of them clearly, you have the signal you came for.

• Intake: Do you screen trauma symptoms, substance use, withdrawal risk, medical history, and suicide risk before proposing a plan? ^{1, 8}
• Stabilization: Which substances do you medically manage on-site, and who is clinically licensed and awake overnight?
• Abstinence rule: Do I need to be sober before trauma-focused therapy can begin? (The current answer should be no.) ^{1, 2}
• Therapies by name: Which of prolonged exposure, cognitive processing therapy, TF-CBT, or EMDR do your clinicians deliver, and how recently were they trained? ^{3, 4}
• Medications: How do you handle benzodiazepine requests, and who coordinates my PTSD medications with my substance-use prescriber? ^{9, 10}
• Discharge: Who schedules my first outpatient appointment, what documents go with me, and who do I call after hours?

Write the answers down. A program that earns your trust will sound like a clinician, not a closer.